ADIPOR1 and metabolic dysfunction-associated steatotic liver disease: In the liver, activation of AdipoR1 and AdipoR2 induces the activation of AMPK pathways and PPARα pathways, respectively, which makes the AdipoRs as a potential drug target for NAFLD therapy 14.